Dr. Yung is a professor of Neuro-Oncology at The University of Texas MD Anderson Cancer Center, where he holds the Margaret and Ben Love Chair of Clinical Cancer Care.
He was chair of the Department of Neuro-oncology (1999-2015) and co-director (1999-2015) of the MDACC Brain Tumor Center. During his tenure, the department has achieved much, including approval of Temozolomide and Bevacizumab by the FDA for GBM, development and funding of the National Cancer Institute (NCI)-funded Brain Tumor SPORE, building of the D24 smart oncolytic virus program, leadership in the NCI- funded CNS tumor clinical trial consortia and creation of the GBM AGILE, a global adaptive clinical trial platform.
Dr. Yung has served as editor-in-chief of Neuro-Oncology (2007-2014), and co-chair of the NCI Brain Malignancy Steering Committee (2011-2017). He was appointed to Vice President Biden’s Cancer Moonshot Blue Ribbon Panel in 2016. He is currently serving as Special Scientific Advisor of National Brain Tumor Society (NBTS), Chair of SAB for Asia Foundation for Cancer Research (AFCR), member of SAC for Ludwig Institute of Cancer Research (LICR), member of SAB for DNA Trix, Member of SAB for Interleukin CTI, Member of SAB for Quadriga, and a member of the MDACC Moonshot executive committee.
Dr. W. K. Alfred Yung received his undergraduate degree from the University of Minnesota, Minneapolis in 1971, graduating summa cum laude. For his medical training, he attended the University of Chicago, Pritzker School of Medicine and received his M.D. degree in 1975. Internship and residency training followed at the University of California, San Diego from 1975 to 1978, and chief residency and fellowship positions, respectively, at the Cornell University School of Medicine and Memorial Sloan Kettering Cancer Center from 1978 to 1981.
